OverviewSuggest Edit

ADMA Biologics is a late-stage biopharmaceutical company that develops, manufactures and intends to commercialize specialty plasma-based biologics for the treatment and prevention of Primary Immune Deficiency Disease and certain infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics.  Its targeted patient populations are immune-compromised individuals suffering from an underlying immune deficiency disorder or may be immune-suppressed for medical reasons.

TypePublic
Founded2004
HQRamsey, US
Websiteadmabiologics.com
Employee Ratings1

Latest Updates

Employees (est.) (Jan 2018)92
Revenue (FY, 2018)$17 M(-25%)
Share Price (Mar 2019)$4 (+2%)

Key People/Management at ADMA Biologics

Bryant E. Fong

Bryant E. Fong

Director
Dov Goldstein

Dov Goldstein

Director
James Mond

James Mond

Chief Scientific and Medical Officer
Brian Lenz

Brian Lenz

Vice President, Chief Financial Officer
Eric I. Richman

Eric I. Richman

Director & Chairperson
Jerrold B. Grossman

Jerrold B. Grossman

Founder and Vice Chairman
Show more

ADMA Biologics Office Locations

ADMA Biologics has offices in Ramsey and Boca Raton
Ramsey, US (HQ)
465 NJ-17, Ramsey, NJ 07446, USA
Boca Raton, US
5800 Park of Commerce Blvd
Show all (2)
Report incorrect company information

ADMA Biologics Financials and Metrics

ADMA Biologics Revenue

ADMA Biologics's revenue was reported to be $16.99 m in FY, 2018
USD

Revenue (FY, 2018)

17.0m

Net income (FY, 2018)

(65.7m)

EBIT (FY, 2018)

(60.3m)

Market capitalization (15-Mar-2019)

184.9m

Closing stock price (15-Mar-2019)

4.0

Cash (31-Dec-2018)

22.8m

EV

188.6m
ADMA Biologics's current market capitalization is $184.9 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

3.1m5.9m7.2m10.7m22.8m17.0m

Revenue growth, %

93%21%49%

General and administrative expense

4.4m6.7m8.5m18.1m22.5m

R&D expense

9.3m7.0m7.7m6.2m3.9m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Revenue

1.1m1.6m1.5m1.4m1.5m1.3m1.9m2.1m2.3m2.9m2.6m3.4m4.7m4.0m4.7m4.2m

General and administrative expense

845.3k1.1m1.5m1.0m1.3m1.4m2.1m1.7m1.7m1.8m4.3m4.4m4.2m5.0m5.0m5.4m

R&D expense

1.4m4.3m1.8m1.5m1.4m1.5m2.1m2.0m3.4m1.7m1.2m1.4m1.8m1.3m1.5m1.3m

Operating expense total

3.6m7.2m5.1m4.4m4.7m4.8m6.5m6.3m7.8m6.7m8.6m11.8m19.2m20.6m18.1m18.0m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

26.1m17.2m10.4m9.9m43.1m22.8m

Accounts Receivable

384.0k924.5k1.0m3.9m1.4m

Inventories

1.7m1.7m3.4m5.0m12.6m18.6m

Current Assets

31.1m24.1m21.3m21.7m63.2m44.5m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Cash

5.4m26.5m17.9m14.0m16.6m7.8m9.2m8.9m12.5m7.9m8.5m25.6m13.6m26.1m55.2m42.4m

Accounts Receivable

335.1k484.4k803.5k562.2k351.4k522.5k1.2m944.0k826.7k1.3m839.9k2.3m1.5m3.7m3.8m4.1m

Inventories

1.2m984.5k1.1m1.5m1.9m2.5m2.8m4.0m4.2m4.6m5.3m13.2m13.4m12.4m12.2m13.9m

Current Assets

7.1m30.8m26.5m22.6m31.0m27.1m25.2m17.4m29.5m25.4m15.7m44.3m31.4m46.4m73.6m62.5m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(15.5m)(16.8m)(18.0m)(19.5m)(43.8m)(65.7m)

Depreciation and Amortization

210.6k247.9k469.8k469.6k2.7m3.4m

Inventories

(403.5k)(39.7k)(1.7m)(1.6m)589.3k(6.0m)

Accounts Payable

1.6m(937.8k)308.7k476.8k2.8m(20.5k)
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Net Income

(2.7m)(5.9m)(9.9m)(13.2m)(3.6m)(8.3m)(13.4m)(4.6m)(10.6m)(15.0m)(6.5m)(30.8m)(17.8m)(32.6m)(47.7m)

Depreciation and Amortization

96.9k151.1k234.7k352.6k234.4k351.7k118.1k1.2m829.5k1.7m2.5m

Inventories

556.5k216.5k1.9m(744.1k)(1.1m)4.0m(763.6k)(1.2m)(288.3k)(201.5k)189.4k381.2k(1.2m)

Accounts Payable

(369.8k)(265.8k)1.8m(305.5k)311.9k2.5m1.0m689.4k1.3m5.2m(202.8k)(2.8m)(653.2k)
USDY, 2018

EV/EBIT

-3.1 x

EV/CFO

-3 x

Revenue/Employee

184.6k

Financial Leverage

4.5 x
Show all financial metrics
Report incorrect company information

ADMA Biologics News and Updates

ADMA Biologics Reports Full Year 2018 Financial Results

RAMSEY, N.J. and BOCA RATON, Fla., March 13, 2019 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that manufactures, markets and develops specialty plasma-derived biologics …

ADMA Biologics to Present at Upcoming Investor Conferences

Raymond James 40th Annual Institutional Investors ConferenceOppenheimer’s 29th Annual Healthcare Conference

ADMA Biologics Enters Into $72.5 Million Loan Facility with Perceptive Advisors

Provides Funding to Support Ongoing Activities Including Inventory Ramp, Plant Expansion, Product Launch and Plasma Collection Center Development Provides Funding to Support Ongoing Activities Including Inventory Ramp, Plant Expansion, Product Launch and Plasma Collection Center Development

As Per New Research, Global Blood safety Market Growth – Report Studied Growing Factors Forecasts To 2024 along with key players such as ADMA Biologics Inc., Baxter International Inc., Creat Group, Octapharma AG, Shire Plc and TCS Biosciences Ltd.

“Blood has been called the river of life, and for good reason. Blood transports life-sustaining oxygen and nutrients. Blood safety Vigilance is needed to help ensure proper balance between safety and the availability of blood.” Posted via Industry Today. Follow us on Twitter @IndustryToday

ADMA Biologics Provides Regulatory Update on BIVIGAM® PAS Submissions

FDA Issues Complete Response Letter for PAS Drug Substance, Approves PAS for Drug Product

ADMA Biologics Reports Third Quarter 2018 Financial Results

RAMSEY, N.J. and BOCA RATON, Fla., Nov. 08, 2018 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical company that develops, manufactures and markets specialty plasma-based biologics for the treatment of Primary Imm…
Show more
Report incorrect company information

ADMA Biologics Blogs

ADMA Biologics Submits Response and Provides Supplemental Information to FDA for BIVIGAM® Complete Response Letter

RAMSEY, N.J. and BOCA RATON, Fla., Jan. 07, 2019 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that manufactures, markets and develops specialty plasma-derived biologics …

ADMA to Host Conference Call to Discuss Recent Regulatory Update on BIVIGAM® PAS Submissions

Call Scheduled for 9am Eastern Time RAMSEY, N.J. and BOCA RATON, Fla., Dec. 20, 2018 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that manufactures, markets and develops specia…

ADMA Biologics Receives PDUFA Date for RI-002

Resubmission of Biologics License Application (“BLA”) Reinforces the Company’s Commitment to Commercialize Novel Therapies for Immune Compromised Patients to Address Unmet Medical Needs RAMSEY, N.J. and BOCA RATON, Fla., Oct. 17, 2018 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“AD…

ADMA Biologics Provides Regulatory Update for BIVIGAM®

RAMSEY, N.J. and BOCA RATON, Fla., Oct. 11, 2018 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that manufactures, markets and develops specialty plasma-derived biologics …

ADMA BioCenters Receives FDA Approval for Third Plasma Collection Center

RAMSEY, N.J. and MARIETTA, Ga., Oct. 03, 2018 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical company that develops, manufactures and markets specialty plasma-based biologics for the treatment of Primary Immun…

ADMA Biologics Resubmits Biologics License Application for RI-002

RAMSEY, N.J. and BOCA RATON, Fla., Oct. 01, 2018 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical company that develops, manufactures and markets specialty plasma-based biologics for the treatment of Primary Im…
Show more

ADMA Biologics Frequently Asked Questions

  • When was ADMA Biologics founded?

    ADMA Biologics was founded in 2004.

  • Who are ADMA Biologics key executives?

    ADMA Biologics's key executives are Bryant E. Fong, Dov Goldstein and James Mond.

  • How many employees does ADMA Biologics have?

    ADMA Biologics has 92 employees.

  • What is ADMA Biologics revenue?

    Latest ADMA Biologics annual revenue is $17 m.

  • What is ADMA Biologics revenue per employee?

    Latest ADMA Biologics revenue per employee is $184.6 k.

  • Who are ADMA Biologics competitors?

    Competitors of ADMA Biologics include BTG, Array BioPharma and Clinigen Group.

  • Where is ADMA Biologics headquarters?

    ADMA Biologics headquarters is located at 465 NJ-17, Ramsey, NJ 07446, USA, Ramsey.

  • Where are ADMA Biologics offices?

    ADMA Biologics has offices in Ramsey and Boca Raton.

  • How many offices does ADMA Biologics have?

    ADMA Biologics has 2 offices.